###begin article-title 0
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy
###end article-title 0
###begin p 1
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
###end p 1
###begin p 2
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 276 283 272 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 361 368 357 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 596 603 592 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 974 977 946 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 1335 1342 1303 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1402 1409 1370 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 1500 1505 1464 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 1589 1596 1549 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMGnT1</italic>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 590 595 <span type="species:ncbi:10090">mouse</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 978 983 <span type="species:ncbi:10090">mouse</span>
###xml 1164 1168 <span type="species:ncbi:10090">mice</span>
###xml 1357 1362 <span type="species:ncbi:10090">mouse</span>
###xml 1424 1428 <span type="species:ncbi:10090">mice</span>
###xml 1576 1580 <span type="species:ncbi:10090">mice</span>
###xml 1604 1609 <span type="species:ncbi:10090">mouse</span>
Hypoglycosylation and reduced laminin-binding activity of alpha-dystroglycan are common characteristics of dystroglycanopathy, which is a group of congenital and limb-girdle muscular dystrophies. Fukuyama-type congenital muscular dystrophy (FCMD), caused by a mutation in the fukutin gene, is a severe form of dystroglycanopathy. A retrotransposal insertion in fukutin is seen in almost all cases of FCMD. To better understand the molecular pathogenesis of dystroglycanopathies and to explore therapeutic strategies, we generated knock-in mice carrying the retrotransposal insertion in the mouse fukutin ortholog. Knock-in mice exhibited hypoglycosylated alpha-dystroglycan; however, no signs of muscular dystrophy were observed. More sensitive methods detected minor levels of intact alpha-dystroglycan, and solid-phase assays determined laminin binding levels to be approximately50% of normal. In contrast, intact alpha-dystroglycan is undetectable in the dystrophic Largemyd mouse, and laminin-binding activity is markedly reduced. These data indicate that a small amount of intact alpha-dystroglycan is sufficient to maintain muscle cell integrity in knock-in mice, suggesting that the treatment of dystroglycanopathies might not require the full recovery of glycosylation. To examine whether glycosylation defects can be restored in vivo, we performed mouse gene transfer experiments. Transfer of fukutin into knock-in mice restored glycosylation of alpha-dystroglycan. In addition, transfer of LARGE produced laminin-binding forms of alpha-dystroglycan in both knock-in mice and the POMGnT1 mutant mouse, which is another model of dystroglycanopathy. Overall, these data suggest that even partial restoration of alpha-dystroglycan glycosylation and laminin-binding activity by replacing or augmenting glycosylation-related genes might effectively deter dystroglycanopathy progression and thus provide therapeutic benefits.
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C1">1</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C2">2</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C3">3</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C6">6</xref>
###xml 402 407 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMT1</italic>
###xml 409 414 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMT2</italic>
###xml 416 423 412 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMGnT1</italic>
###xml 425 432 421 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 434 438 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FKRP</italic>
###xml 443 448 439 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 664 665 656 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 711 712 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C7">7</xref>
###xml 713 714 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C8">8</xref>
Dystroglycanopathy is a group of congenital and limb-girdle muscular dystrophies that includes Walker-Warburg syndrome (WWS), muscle-eye-brain (MEB) disease, Fukuyama-type congenital muscular dystrophy (FCMD), congenital muscular dystrophy 1C/D (1,2) and limb-girdle muscular dystrophy (LGMD) 2I/K/M/N (3-6). Hypoglycosylation of alpha-dystroglycan is a hallmark of these disorders. So far, six genes (POMT1, POMT2, POMGnT1, fukutin, FKRP and LARGE) have been implicated in dystroglycanopathies and all are thought to be involved in glycosylation of alpha-dystroglycan. POMGnT1 and the POMT1/2 complexes are known to have glycosyltransferase activities that place O-mannosyl sugar chains on alpha-dystroglycan (7,8). The exact functions of fukutin, FKRP and LARGE are still unknown.
###end p 5
###begin p 6
###xml 188 189 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C9">9</xref>
###xml 313 314 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 457 458 435 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 533 535 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C10">10</xref>
###xml 621 622 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 519 522 <span type="species:ncbi:9606">Man</span>
alpha-Dystroglycan (alpha-DG) is a receptor for laminin in the basement membrane and is anchored on the plasma membrane through non-covalent interaction with a transmembrane-type beta-DG (9). alpha- and beta-DGs are encoded by a single mRNA that is cleaved into two subunits during post-translational maturation. O-glycosylation of alpha-DG is required for ligand-binding activity. Although the exact binding epitope for ligand is still unknown, one unique O-mannosyl glycan [Neu5Ac(alpha2-3)Gal(beta1-4)GlcNAc(beta1-2)Man-Ser/Thr] (10) appears to be involved in ligand binding among extensive and heterogenous groups of O-linked sugar chains. beta-DG interacts with dystrophin, which in turn binds to actin filaments. The DG complex spans the plasma membrane, connecting the basement membrane to the actin cytoskeleton and presumably conferring mechanical stability to muscle cells during muscle contraction.
###end p 6
###begin p 7
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C11">11</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C12">12</xref>
###xml 612 619 612 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C13">13</xref>
###xml 725 728 725 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Alu</italic>
###xml 780 787 780 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 1032 1034 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C13">13</xref>
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C15">15</xref>
###xml 1154 1155 1154 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C5">5</xref>
###xml 1156 1158 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C16">16</xref>
###xml 1159 1161 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C19">19</xref>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
In Japan, FCMD is the most common congenital muscular dystrophy and, following Duchenne muscular dystrophy, is the second most common childhood muscular dystrophy. An autosomal recessive disorder, FCMD is characterized by severe muscular dystrophy, abnormal neuronal migration associated with mental retardation and epilepsy and, frequently, eye abnormalities (11). A recent study revealed aberrant neuromuscular junction formation and delayed muscle terminal maturation in FCMD, suggesting that a maturational delay of muscle fibers underlies the etiology of FCMD (12). Through positional cloning we identified fukutin, the gene responsible for FCMD (13). The predominant mutation in FCMD was identified as a 3 kb SINE-VNTR-Alu (SVA) retrotransposon insertion into the 3'-UTR of fukutin. In Japan, 70-80% of FCMD patients are homozygous for this retrotransposal insertion. Compound heterozygosity, exhibiting both a retrotransposonal mutation and a point mutation, is sometimes seen and generally exhibits more severe pathologies (13-15). Only a few cases with non-founder mutations (homozygous for point mutations) have been reported outside of Japan (5,16-19).
###end p 7
###begin p 8
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMGnT1</italic>
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 251 252 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 286 287 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C7">7</xref>
###xml 396 398 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C20">20</xref>
###xml 410 413 403 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 557 560 546 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 629 631 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C20">20</xref>
###xml 632 634 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C21">21</xref>
###xml 715 720 704 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Large</italic>
###xml 727 729 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C22">22</xref>
###xml 868 870 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C23">23</xref>
###xml 873 878 862 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 932 934 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C24">24</xref>
###xml 1094 1096 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C25">25</xref>
###xml 1097 1099 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C26">26</xref>
###xml 1236 1238 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C25">25</xref>
###xml 414 419 <span type="species:ncbi:10090">mouse</span>
###xml 512 517 <span type="species:ncbi:9606">human</span>
###xml 561 565 <span type="species:ncbi:10090">mice</span>
###xml 906 911 <span type="species:ncbi:9606">human</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
MEB disease is a severe autosomal recessive disease, similar to FCMD, characterized by congenital muscular dystrophy, ocular abnormalities and brain malformation. The gene responsible for MEB is POMGnT1, which encodes protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase 1 (7). In both FCMD and MEB disease, alpha-DG glycosylation and laminin-binding activity are severely disrupted (20). The Largemyd mouse, a spontaneous mutant, has been used as a model for dystroglycanopathy. As is the case with human dystroglycanopathies, alpha-DG in Largemyd mice is hypoglycosylated and shows reduced ligand-binding activity (20,21). Positional cloning in this model identified a disease-causing mutation in the Large gene (22), which encodes a protein with a transmembrane domain followed by a coiled-coil domain and two DxD-containing putative catalytic domains (23). LARGE mutations are also seen in human dystroglycanopathy (24). Although the exact function of the LARGE protein is not fully understood, it has been shown to produce hyperglycosylated alpha-DG in culture cells and mice (25,26). In addition, physical interaction between LARGE and alpha-DG is an essential step in acquiring ligand-binding activities of alpha-DG (25). Therefore, it is believed that LARGE plays a post-translational role in modulating both alpha-DG glycosylation and its functional expression.
###end p 8
###begin p 9
###xml 190 197 190 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C27">27</xref>
###xml 332 339 332 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 339 342 339 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C28">28</xref>
###xml 645 652 645 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
###xml 376 380 <span type="species:ncbi:10090">Mice</span>
###xml 591 596 <span type="species:ncbi:10090">mouse</span>
To further investigate molecular pathogenesis and to explore therapeutic strategies for dystroglycanopathy, we generated several model mice for FCMD. We first generated mice with a targeted fukutin disruption, but this model showed embryonic lethality (27). We also generated chimeric fukutin mice by injecting homozygous targeted (fukutin-/-) ES cells into blastocysts (28). Mice with high chimerism showed dystrophic skeletal muscle; however, the variability of chimerism among individuals, and with growth, limits this experimental approach. Therefore, we generated a transgenic knock-in mouse model carrying the retrotransposal insertion in fukutin. Our data revealed that even a small amount of intact alpha-DG is sufficient to maintain skeletal muscle function, and suggest that increasing the expression of glycosylation-related genes, which could be accomplished through various approaches, can be a therapeutic strategy for preventing or slowing progression of a broad range of dystroglycanopathies.
###end p 9
###begin title 10
RESULTS
###end title 10
###begin title 11
###xml 20 24 <span type="species:ncbi:10090">mice</span>
Generation of model mice for FCMD
###end title 11
###begin p 12
###xml 98 105 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F1">1</xref>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F1">1</xref>
###xml 875 876 875 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F1">1</xref>
###xml 991 992 991 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 1047 1054 1047 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 1098 1099 1098 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F1">1</xref>
###xml 1167 1174 1167 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 1419 1426 1419 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 1522 1524 1522 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C14">14</xref>
###xml 1623 1630 1623 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 1646 1649 1646 1649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1652 1654 1652 1654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C27">27</xref>
###xml 1764 1765 1764 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 1832 1833 1832 1833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
###xml 126 133 <span type="species:ncbi:9606">patient</span>
###xml 381 386 <span type="species:ncbi:9606">human</span>
###xml 410 415 <span type="species:ncbi:9606">human</span>
###xml 448 453 <span type="species:ncbi:9606">human</span>
###xml 454 461 <span type="species:ncbi:9606">patient</span>
###xml 521 526 <span type="species:ncbi:9606">human</span>
###xml 543 550 <span type="species:ncbi:9606">patient</span>
###xml 754 758 <span type="species:ncbi:10090">mice</span>
###xml 851 856 <span type="species:ncbi:10090">mouse</span>
###xml 912 916 <span type="species:ncbi:10090">mice</span>
###xml 1087 1091 <span type="species:ncbi:10090">mice</span>
###xml 1154 1158 <span type="species:ncbi:10090">mice</span>
###xml 1248 1252 <span type="species:ncbi:10090">mice</span>
###xml 1341 1346 <span type="species:ncbi:9606">Human</span>
###xml 1347 1355 <span type="species:ncbi:9606">patients</span>
###xml 1555 1559 <span type="species:ncbi:10090">mice</span>
###xml 1565 1580 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1705 1709 <span type="species:ncbi:10090">mice</span>
###xml 1788 1792 <span type="species:ncbi:10090">mice</span>
To generate a transgenic knock-in mouse carrying the retrotransposal insertion, we replaced mouse fukutin exon 10 with a FCMD patient's exon 10, engineered to contain the retrotransposal insertion using a site-directed DNA integration technique. Exon 10 encodes amino acids from Tyr-392 to the C-terminal end and the 3'-UTR. We also generated another transgene containing a normal human exon 10. The terms Hn (human normal; Fig. 1A, no. 6) and Hp (human patient; Fig. 1A, no. 7) refer to transgenes containing the normal human exon 10 and the patient's exon 10, respectively. Recombination was confirmed using Southern blot analysis of genomic DNA from ES cells (data not shown). Targeted ES cell clones were injected into blastocysts to obtain chimeric mice. Germline transmission of the knock-in allele was established via Southern blot analysis of mouse genomic DNA (Fig. 1B). Germline-competent heterozygous mice were in turn mated to generate homozygous mutants (Hn/Hn and Hp/Hp) (Fig. 2A, nos 3 and 4). RT-PCR showed a dramatic reduction of fukutin mRNA transcript levels in Hp/Hp mice (Fig. 1C). Through quantitative PCR, we determined that Hp/Hp mice express fukutin transcript at 5-10% of normal levels (data not shown). We consider Hp/Hp mice to be models for most FCMD cases that are homozygous for the retrotransposal insertion. Human patients who are compound heterozygous for the insertion and a nonsense fukutin mutation generally show more severe pathology than those who are homozygous for the insertion (14). Therefore, we crossed Hp/Hp mice with transgenic mice carrying a neo cassette disruption of one fukutin allele (fukutin+/-) (27) to create a compound heterozygous line. The Hp/+ mice in this line represent retrotransposon carriers (Fig. 2A, no. 5) and the Hp/- mice represent compound heterozygotes (Fig. 2A, no. 6).
###end p 12
###begin p 13
###xml 84 91 84 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 99 100 99 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 218 225 218 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 294 295 294 295 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 520 521 520 521 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 540 547 540 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
###xml 212 217 <span type="species:ncbi:9606">Human</span>
###xml 323 328 <span type="species:ncbi:10090">mouse</span>
###xml 359 364 <span type="species:ncbi:9606">human</span>
Generation of FCMD model mice that carry the retrotransposal insertion in the mouse fukutin gene. (A) Schematic representation of the targeting vector. Details are described in the Materials and Methods section. Human fukutin exon10 is shown in green, and the retrotransposon is shown in red. (B) Southern blot analysis of mouse genomic DNA. Insertion of the human exon10 with the retrotransposon yields new 3.1 kb BamHI/Bgl II and 5.6 kb fragments that hybridize, respectively, with the 5' and 3' probes shown in (A). (C) RT-PCR analysis. fukutin transcripts were amplified using RT-PCR. A beta-actin internal control is shown (bottom panel).
###end p 13
###begin p 14
###xml 69 70 69 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 123 130 123 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 210 217 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 369 376 369 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 523 530 523 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 627 628 627 628 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 629 630 629 630 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 180 184 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 327 331 <span type="species:ncbi:10090">mice</span>
###xml 363 368 <span type="species:ncbi:10090">mouse</span>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 517 522 <span type="species:ncbi:9606">human</span>
###xml 675 679 <span type="species:ncbi:10090">mice</span>
###xml 770 775 <span type="species:ncbi:10090">mouse</span>
###xml 1160 1164 <span type="species:ncbi:10090">mice</span>
###xml 1338 1342 <span type="species:ncbi:10090">mice</span>
###xml 1371 1375 <span type="species:ncbi:10090">mice</span>
FCMD models exhibit hypoglycosylation and laminin-binding activity. (A) Schematic representation of the control and mutant fukutin genes in model mice. 1, wild-type mice (+/+); 2, mice carrying a neo-disrupted fukutin allele (+/-); 3, mice homozygous for the Hn allele (Hn/Hn); 4, mice homozygous for the Hp allele (Hp/Hp); 5, mice with a Hp allele and an intact mouse fukutin allele (Hp/+); and 6, mice with a Hp allele and a neo-disrupted allele (Hp/-). Exons are indicated with filled boxes. Portions derived from human fukutin exon 10 are shown in orange and green (3'-UTR). The retrotransposal insertion is shown in red. (B-F) Biochemical characterization of FCMD model mice. WGA beads were added to solubilized skeletal muscle samples to enrich DG from each model mouse. FCMD models are shown in red (Hp/Hp and Hp/-). WGA preparations were analyzed by western blot using antibodies against core protein (B) and glycosylated alpha-DG (C). The western blot for beta-DG shows comparable amounts of DG proteins in each lane (D). Overexposure of blots analyzing core protein and glycosylated alpha-DG detected the presence of intact alpha-DG proteins in Hp/- mice (E). The portions of normal-sized and hypoglycosylated alpha-DGs are indicated at the right side of the blots. A laminin overlay assay was performed using samples from Hp/- mice and the litter control Hp/+ mice (F).
###end p 14
###begin title 15
###xml 11 15 <span type="species:ncbi:10090">mice</span>
FCMD model mice exhibit hypoglycosylation of alpha-DG
###end title 15
###begin p 16
###xml 237 239 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C20">20</xref>
###xml 240 242 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C29">29</xref>
###xml 540 542 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C20">20</xref>
###xml 715 716 679 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 809 810 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 925 926 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 1045 1046 985 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 1183 1184 1111 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 1307 1308 1223 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 1569 1570 1466 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 1887 1888 1764 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 2066 2067 1939 1940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 140 145 <span type="species:ncbi:4565">wheat</span>
###xml 311 315 <span type="species:ncbi:9925">goat</span>
###xml 703 707 <span type="species:ncbi:10090">mice</span>
###xml 798 802 <span type="species:ncbi:10090">mice</span>
###xml 842 846 <span type="species:ncbi:10090">mice</span>
###xml 1034 1038 <span type="species:ncbi:10090">mice</span>
###xml 1263 1267 <span type="species:ncbi:10090">mice</span>
###xml 1579 1583 <span type="species:ncbi:10090">mice</span>
###xml 1649 1653 <span type="species:ncbi:10090">mice</span>
###xml 1679 1683 <span type="species:ncbi:10090">mice</span>
###xml 1778 1782 <span type="species:ncbi:10090">mice</span>
###xml 2004 2008 <span type="species:ncbi:10090">mice</span>
###xml 2118 2122 <span type="species:ncbi:10090">mice</span>
To characterize the biochemical properties of alpha-DG in the knock-in mice, we prepared skeletal muscle samples enriched for alpha-DG with wheat germ agglutinin (WGA) beads, which is able to bind nearly all the DG in the muscle sample (20,29). These preparations were analyzed using western blot analysis with goat polyclonal antibodies against alpha-DG core protein (AP-074G-C) and the monoclonal antibody IIH6. IIH6 recognizes glycosylated epitopes on alpha-DG, and hypoglycosylation results in the absence of epitopes for the antibody (20). Western blot analysis of alpha-DG core protein revealed the presence of approximately150 kDa alpha-DG proteins in the control group (+/+, +/-, Hn/Hn and Hp/+ mice) (Fig. 2B, lanes 1-3 and 5). A slight reduction in molecular weight was observed in Hp/Hp mice (Fig. 2B, lane 4, upper band). In Hp/- mice, we observed a much-reduced intensity of the approximately150 kDa bands (Fig. 2B, lane 6). In addition, lower molecular weight (approximately90 kDa) bands were detected in Hp/Hp and Hp/- mice (Fig. 2B, lanes 4 and 6). Western blotting with IIH6 detected approximately150 kDa bands in the control groups (+/+, +/-, Hn/Hn and Hp/+) (Fig. 2C, lanes 1-3 and 5). IIH6 reactivity at approximately150 kDa in Hp/Hp and Hp/- mice was reduced relative to controls (Fig. 2C, lanes 4 and 6). alpha-DG proteins with reduced molecular weight (approximately90 kDa) were not recognized by IIH6, indicating that they are hypoglycosylated. Western blot analysis of beta-DG confirmed comparable levels of DG proteins among the samples (Fig. 2D). Hp/- mice consistently contained more hypoglycosylated alpha-DG than Hp/Hp mice; therefore, we used Hp/- mice as models for FCMD and their Hp/+ littermates as controls. Longer exposure of blots from Hp/- mice detected an alpha-DG species recognized by IIH6 with the molecular weight of approximately150 kDa (Fig. 2E), suggesting that a small amount of intact alpha-DG also is present. Analysis of laminin-binding activity in Hp/- mice and Hp/+ littermates using a laminin overlay assay (Fig. 2F) showed reduced laminin-binding activity in Hp/- mice.
###end p 16
###begin title 17
A small amount of intact alpha-DG prevents muscular dystrophy
###end title 17
###begin p 18
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F3">3</xref>
###xml 678 679 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F3">3</xref>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 482 488 <span type="species:ncbi:9606">humans</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
We examined hematoxylin and eosin (H&E) stained sections of the quadriceps, gastrocnemius, tibialis anterior, soleus, iliopsoas and diaphragm muscles in Hp/+ and Hp/- mice. H&E staining revealed no clear difference between Hp/+ and Hp/- mice. Histopathological features of muscular dystrophy, such as centrally located nuclei, tissue fibrosis and fatty infiltration were not observed in 10-week-old FCMD models Hp/- (Fig. 3A) and Hp/Hp mice (data not shown). Although FCMD onset in humans occurs at or near birth, we also examined older mice to determine whether onset in Hp/- mice was delayed. Even in older mice (>1 year old), we observed no signs of muscular dystrophy (Fig. 3B). There was no obvious change in the expression level of laminin alpha2 chain, which is the major ligand of alpha-DG in the skeletal muscle ().
###end p 18
###begin p 19
###xml 145 146 145 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 161 162 161 162 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 5 9 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 291 295 <span type="species:ncbi:10090">mice</span>
FCMD mice do not develop a muscular dystrophy phenotype. Various skeletal muscle tissues from Hp/- and littermate control Hp/+ mice at 10 weeks (A) and >1 year (B) of age were analyzed by H&E staining. No features of muscular dystrophy or other variation from controls were observed in Hp/- mice.
###end p 19
###begin p 20
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
Both hypoglycosylated and IIH6-positive intact alpha-DG proteins were detected in Hp/Hp and Hp/- mouse brains (). As is the case with skeletal muscle, Hp/- mice contained more hypoglycosylated alpha-DG. Apparent brain histological abnormality was hardly detected in Hp/- mice; only a few mice showed a very small ectopic cluster of neurons migrating into the marginal zone. We also analyzed alpha-DG in heart, liver, and lung from Hp/- mice, and found that the levels of hypoglycosylation and laminin-binding activity vary between the tissues (less affected in heart and liver) ().
###end p 20
###begin p 21
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C30">30</xref>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 460 464 <span type="species:ncbi:10090">mice</span>
To analyze potential weakness in muscle cell membrane integrity, which may not be detectable in housed mice by H&E staining, Hp/- mice were subjected to treadmill exercise followed by the measurement of Evans blue dye (EBD) incorporation into muscle fibers. EBD is a membrane-impermeant molecule that binds to serum albumin and is physically restricted from fibers unless the skeletal muscle membrane is damaged (30). Even after exercising to exhaustion, Hp/- mice showed no EBD uptake in muscle cells (data not shown).
###end p 21
###begin p 22
###xml 406 409 398 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 512 514 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C21">21</xref>
###xml 664 665 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F4">4</xref>
###xml 839 840 811 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F4">4</xref>
###xml 1133 1134 1097 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F4">4</xref>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
###xml 383 387 <span type="species:ncbi:10090">mice</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
###xml 917 921 <span type="species:ncbi:10090">mice</span>
###xml 984 988 <span type="species:ncbi:10090">mice</span>
###xml 1107 1111 <span type="species:ncbi:10090">mice</span>
###xml 1208 1212 <span type="species:ncbi:10090">mice</span>
###xml 1251 1255 <span type="species:ncbi:10090">mice</span>
Reduction of laminin-binding activity due to hypoglycosylation of alpha-DG is thought to be the main cause of dystroglycanopathy. Therefore, we hypothesized that the minimal levels of intact alpha-DG species observed in Hp/- mice are sufficient to maintain linkage to laminin and prevent disease progression. To test this hypothesis, we compared the laminin-binding activity in Hp/- mice with that in Largemyd (myd/myd) mice, which represent another dystroglycanopathy model with a muscular dystrophy phenotype (21). H&E analysis confirmed signs of muscular dystrophy (centrally located nuclei and fiber size variation) in myd/myd mice, but not in Hp/- mice (Fig. 4A and B). In contrast with Hp/- mice, western blot analysis of alpha-DG core protein in myd/myd mice revealed no intact size (approximately150 kDa) of alpha-DG species (Fig. 4C and D), indicating that almost all alpha-DG is hypoglycosylated in myd/myd mice. The laminin-binding activity of alpha-DG in Hp/- and myd/myd mice was measured using a quantitative solid-phase laminin-binding assay and compared with litter controls (Hp/+ and myd/+ mice, respectively) (Fig. 4E and F). Laminin-binding activity was approximately50% of normal in Hp/- mice but less than 5% of normal in myd/myd mice. The solid-phase binding analysis shows no obvious difference between wild-type and Hp/+. These data demonstrate that levels of glycosylation (indicated by IIH6 immunoreactivity and the presence of approximately150 kDa alpha-DG) influence laminin-binding activity and indicate that only a small amount of IIH6-reactive alpha-DG is required to maintain skeletal muscle function.
###end p 22
###begin p 23
###xml 80 83 80 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 135 136 135 136 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 162 163 162 163 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 213 214 213 214 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 233 234 233 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 370 371 366 367 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 386 387 382 383 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
Laminin-binding activity is maintained in Hp/- mice but barely detected in Largemyd mice. H&E staining of quadriceps tissue from Hp/- (A) and Largemyd (myd/myd) (B) mice are shown. WGA preparations from the Hp/- (C) and the myd/myd (D) skeletal muscle were also analyzed by western blot using an antibody against alpha-DG core protein. Laminin-binding activity in Hp/- (E) and myd/myd (F) mice were measured using solid-phase binding assays and compared to the littermate controls (Hp/+ and myd/+). Open squares (gray line) in panel E indicate laminin-binding activity in wild-type mice.
###end p 23
###begin title 24
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Fukutin gene transfer restores glycosylation of alpha-DG in knock-in mice
###end title 24
###begin p 25
###xml 205 212 201 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 563 570 551 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 743 744 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F5">5</xref>
###xml 833 840 789 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 876 877 832 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F5">5</xref>
###xml 978 979 934 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F5">5</xref>
###xml 1029 1036 985 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 1104 1111 1056 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
Our data strongly suggest that even partial restoration of alpha-DG glycosylation is effective in reducing disease severity in dystroglycanopathy. To examine whether glycosylation defects can be recovered in vivo, a recombinant fukutin adenovirus was injected into the hind limb muscle of 3-day-old Hp/- and litter control Hp/+ mice. Following 4 weeks of injections, alpha-DG enriched samples were prepared using WGA beads and analyzed for glycosylation and laminin-binding activity. Western blot analysis with anti-alpha-DG core protein antibodies revealed that fukutin gene transfer into Hp/- mice reduced hypoglycosylated alpha-DG (approximately90 kDa) and increased levels of the normal-sized alpha-DG species (approximately150 kDa) (Fig. 5A, lanes 3 and 4). IIH6 reactivity and laminin-binding activity also increased following fukutin gene transfer into Hp/- mice (Fig. 5B and C, lanes 3 and 4). No obvious changes were observed in Hp/+ mice after the gene transfer (Fig. 5C, lanes 1 and 2). These results demonstrate that fukutin gene transfer can correct biochemical abnormalities of alpha-DG in fukutin-deficient skeletal muscle, and support that fukutin protein is involved in glycosylation of alpha-DG.
###end p 25
###begin p 26
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fukutin</italic>
###xml 147 154 147 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 307 308 303 304 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 337 338 329 330 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 375 376 367 368 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 391 398 383 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 141 146 <span type="species:ncbi:9606">human</span>
###xml 216 220 <span type="species:ncbi:9913">Calf</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
Fukutin gene transfer rescues the glycosylation abnormality in Hp/- mice. Hp/+ or Hp/- pups were injected with adenovirus encoding wild-type human fukutin in one leg (+) and with saline in the contralateral leg (-). Calf muscle was analyzed using western blot with antibodies against core alpha-DG protein (A) and glycosylated alpha-DG (B) and using a laminin overlay assay (C). Transfer of fukutin produced increases in alpha-DG molecular weight, IIH6 reactivity and laminin binding activity in Hp/- mice.
###end p 26
###begin title 27
Large gene transfer produces laminin-binding forms of alpha-DG in dystroglycanopathy models
###end title 27
###begin p 28
###xml 93 100 93 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMGnT1</italic>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMT1</italic>
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMT2</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FKRP</italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 661 663 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C26">26</xref>
Hypoglycosylation leading to dystroglycanopathies is caused by mutations in six known genes (fukutin, POMGnT1, POMT1, POMT2, FKRP and LARGE) and other, unidentified genes. In an effort to bypass the need for identification of disease-causing genes in developing therapies (e.g. gene transfer), we further explored a unique feature of LARGE. LARGE has been demonstrated to induce alpha-DG hyperglycosylation, which is detected by IIH6 as a broad band detected at 150-300 kDa via SDS gel electrophoresis. This band shows increased ligand-binding activity in samples from genetically distinct diseases showing defective alpha-DG glycosylation (FCMD, MEB and WWS) (26).
###end p 28
###begin p 29
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 272 273 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F6">6</xref>
###xml 277 282 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 454 455 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F6">6</xref>
###xml 459 464 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 665 670 653 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 855 856 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F6">6</xref>
###xml 965 966 933 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F6">6</xref>
###xml 1013 1015 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C26">26</xref>
###xml 1032 1037 1000 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 1113 1114 1077 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F6">6</xref>
###xml 1354 1355 1314 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F6">6</xref>
###xml 1455 1462 1411 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
We examined whether adenoviral LARGE gene transfer into Hp/- skeletal muscle induces hyperglycosylation and increases laminin-binding activity of alpha-DG. Immunofluorescence analysis of untreated control muscles revealed weaker IIH6 reactivity in Hp/- than in Hp/+ (Fig. 6A, -LARGE). Muscle sections subjected to gene transfer showed increased alpha-DG glycosylation in transduced areas, as indicated by eGFP expression in both Hp/- and Hp/+ mice (Fig. 6A, +LARGE). We also examined adenovirus-injected and non-injected contralateral leg muscles using western blot analysis with antibodies against alpha-DG core protein and IIH6. These experiments showed that the LARGE gene transfer increased IIH6 reactivity at approximately150 kDa in the Hp/- muscle and produced a broad band with a molecular weight of 150-250 kDa in both Hp/- and Hp/+ muscles (Fig. 6B). Anti-alpha-DG core protein antibodies poorly recognized a higher molecular weight alpha-DG species (Fig. 6C), which is consistent with previous reports (26). Following the LARGE gene transfer, levels of hypoglycosylated alpha-DG species decreased (Fig. 6C, lanes 3 and 4). These data indicate that LARGE-induced glycosylation occurs on hypoglycosylated alpha-DG species. The IIH6-positive broad-molecular-weight band was able to bind laminin in both Hp/- and Hp/+ skeletal muscle samples (Fig. 6D, lanes 2 and 4). These data indicate that LARGE can increase laminin-binding forms of alpha-DG in fukutin-deficient skeletal muscle.
###end p 29
###begin p 30
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 138 143 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 261 262 257 258 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 456 457 448 449 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 483 484 471 472 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 521 522 509 510 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 750 755 731 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:9913">Calf</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
LARGE gene transfer produces functionally glycosylated alpha-DG in Hp/- mice. Hp/+ or Hp/- pups were injected with an adenovirus encoding LARGE in one leg (+) and with saline in the contralateral leg (-). Calf muscle was analyzed using IIH6 immunofluorescence (A). GFP fluorescence represents muscle fibers successfully transduced by the adenoviral vectors. WGA preparations were analyzed using western blots with antibodies against glycosylated alpha-DG (B), alpha-DG core protein (C) and using a laminin overlay assay (D). The western blot for beta-DG shows comparable amounts of DG proteins in each lane. Images with longer-exposures better indicate the presence of hyperglycosylated alpha-DG (arrowheads). These results show that the transfer of LARGE increases IIH6 reactivity and laminin-binding activity in Hp/- mice.
###end p 30
###begin p 31
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 175 182 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMGnT1</italic>
###xml 207 210 203 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 228 233 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 396 399 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 411 412 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F7">7</xref>
###xml 489 490 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F7">7</xref>
###xml 516 517 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F7">7</xref>
###xml 598 601 582 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 682 685 666 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 712 715 696 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 726 729 710 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 748 749 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F7">7</xref>
###xml 863 866 835 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 970 972 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C20">20</xref>
###xml 1066 1069 1038 1041 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1104 1109 1076 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 1205 1206 1177 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F7">7</xref>
###xml 1274 1279 1246 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 1434 1435 1402 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F7">7</xref>
###xml 1475 1478 1443 1446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1565 1568 1533 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1584 1587 1552 1555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1778 1779 1742 1743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F7">7</xref>
###xml 193 198 <span type="species:ncbi:10090">mouse</span>
###xml 221 227 <span type="species:ncbi:8164">Suzuki</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
We further investigated whether LARGE gene transfer induced hyperglycosylation and produced laminin-binding forms of alpha-DG species in another dystroglycanopathy model, the POMGnT1-disrupted mouse (POMGnT1-/-) (Miyagoe-Suzuki et al., manuscript in preparation). Western blot analysis using alpha-DG core protein antibodies showed a reduction of alpha-DG molecular weight to 60-90 kDa in POMGnT1-/- mice (Fig. 7C, lane 4). Little IIH6 reactivity was detected via immunofluorescence (Fig. 7A) and western blot (Fig. 7B, lane 4) analysis. These data indicate hypoglycosylation of alpha-DG in POMGnT1-/- mice. Accordingly, laminin-binding activity was significantly reduced in POMGnT1-/- mice compared with POMGnT1+/- or POMGnT1+/+ littermates (Fig. 7D, lanes 2, 4 and 6). The minor laminin binding protein (approximately80-100 kDa, lane 4) detected only in POMGnT1-/- is unidentified; however, similar laminin binding was also observed in POMGnT1-deficient MEB patients (20). A solid-phase binding assay also showed minor levels of laminin-binding activity in POMGnT1-/- (). For all genotypes, adenoviral LARGE gene transfer increased IIH6 reactivity in transduced areas indicated by eGFP expression (Fig. 7A, +/+, +/-, and -/-). Western blot analysis using IIH6 showed that LARGE gene transfer also induced hyperglycosylation of alpha-DG in all genotypes, as indicated by broad bands with molecular weights from 150 to >250 kDa (Fig. 7B). After the gene transfer, the POMGnT1-/- skeletal muscle showed only hyperglycosylated IIH6-positive species, while the POMGnT1+/+ and the POMGnT1+/- muscles showed both hyperglycosylated and the original 150 kDa IIH6-positive species. Overlay assays showed that the laminin-binding epitope was produced on hyperglycosylated alpha-DG (Fig. 7D). These data support the idea that LARGE is an effective target for increasing or restoring laminin-binding activity of alpha-DG in dystroglycanopathy.
###end p 31
###begin p 32
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 98 101 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 110 113 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 124 127 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 172 177 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 191 196 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 241 246 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 305 306 301 302 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 500 501 492 493 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 530 531 518 519 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 568 569 556 557 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 608 613 596 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 679 682 667 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:9913">Calf</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
LARGE gene transfer produces functionally glycosylated alpha-DG in MEB disease model mice. POMGnT1+/+, POMGnT1+/- or POMGnT1-/- pups were injected with adenovirus encoding LARGE in one leg (+LARGE) and with saline in the contralateral leg (-LARGE). Calf muscle was analyzed using IIH6 immunofluorescence (A). GFP fluorescence represents muscle fibers successfully transduced by the adenoviral vectors. WGA preparations were analyzed using western blots with antibodies against glycosylated alpha-DG (B) and alpha-DG core protein (C) and using a laminin overlay assay (D). These results show that transfer of LARGE increases IIH6 reactivity and laminin-binding activity in POMGnT1-/- mice, the model for MEB disease.
###end p 32
###begin title 33
DISCUSSION
###end title 33
###begin p 34
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C27">27</xref>
###xml 179 186 179 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C28">28</xref>
###xml 533 540 533 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 701 703 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C20">20</xref>
###xml 704 706 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C31">31</xref>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
###xml 527 532 <span type="species:ncbi:10090">mouse</span>
###xml 582 587 <span type="species:ncbi:9606">human</span>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 691 699 <span type="species:ncbi:9606">patients</span>
We have used several approaches to generate FCMD model animals. Fukutin-null mice result in embryonic lethality (27). Fukutin-chimera mice derived from ES cells targeted for both fukutin alleles (28) develop muscular dystrophy, but are inappropriate therapeutic study models because (i) they show wide variation in disease severity, and (ii) muscle cell fusion events during growth and regeneration can alter the population of fukutin-null cells. Therefore, we decided to introduce the disease-causing retrotransposon into the mouse fukutin gene to mimic the most prevalent form of human FCMD. In these knock-in Hp/Hp and Hp/- mice, we detected hypoglycosylated alpha-DG, as is seen in FCMD patients (20,31), so we consider them to be novel models for FCMD.
###end p 34
###begin p 35
###xml 17 20 17 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 30 33 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vls</sup>
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C21">21</xref>
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C32">32</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C33">33</xref>
###xml 358 365 358 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C34">34</xref>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 270 275 <span type="species:ncbi:9606">human</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 430 435 <span type="species:ncbi:9606">human</span>
Spontaneous Largemyd and Largevls mice (21,32) and genetically engineered POMGnT1-deficient mice (33) have been reported as dystroglycanopathy models. Because these models mimic null mutations such as nonsense and frameshift mutations, they do not necessarily represent human diseases caused by missense mutations. Our knock-in mice with the retrotransposal fukutin insertion are the first dystroglycanopathy model that carries a human disease-causing mutation. Such models are needed to explain the molecular pathogenesis of diseases, to determine the function of responsible genes and to screen drugs that correct specific defects (34).
###end p 35
###begin p 36
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 322 324 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C20">20</xref>
###xml 357 360 353 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 691 698 683 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 821 822 813 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F2">2</xref>
###xml 910 912 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C35">35</xref>
###xml 1342 1344 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C36">36</xref>
###xml 1345 1347 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C37">37</xref>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 455 459 <span type="species:ncbi:10090">mice</span>
###xml 708 712 <span type="species:ncbi:10090">mice</span>
###xml 859 864 <span type="species:ncbi:9606">human</span>
###xml 865 873 <span type="species:ncbi:9606">patients</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
###xml 1289 1293 <span type="species:ncbi:10090">mice</span>
###xml 1298 1304 <span type="species:ncbi:9606">humans</span>
Although these mice genetically and biochemically represent features of fukutin-deficient muscular dystrophies, histological analysis has revealed no signs of muscular dystrophy. In typical cases of FCMD, normal-sized alpha-DG with IIH6-reactivity is barely detected, and laminin-binding activity is dramatically reduced (20). Comparing Hp/- mice with Largemyd mice led us to reason that the remaining intact alpha-DG and laminin-binding activity in Hp/- mice might be sufficient to prevent disease progression. In the future, it would be important to elucidate the threshold level of glycosylation required to avoid a phenotype by using a model system that can control glycosylation levels in vivo. In Hp/- mice, residual laminin-binding is detected from DG species with slightly lower molecular weight (<150 kDa) (Fig. 2F), whereas this is not the case for human patients even with retained laminin binding (35). The difference suggests that mice may have additional laminin-binding epitopes, which are less susceptible to fukutin defects. Alternatively, other factors may compensate for reduced laminin-binding to alpha-DG. For example, it has been suggested that integrin alpha7, another laminin receptor in skeletal muscle, may account for the difference in clinical severity between mice and humans with dystrophin- or the DGC-defects (36,37). Clarifying the factors involved would be necessary for a better understanding of pathomechanism, which could promote identification of novel therapeutic targets.
###end p 36
###begin p 37
###xml 228 230 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C35">35</xref>
###xml 242 247 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 373 380 365 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 189 194 <span type="species:ncbi:9606">human</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
Also important is the finding that even a small amount of IIH6-immunoreactivity of alpha-DG is sufficient to maintain skeletal muscle function. This concept is supported by milder cases of human patients with fukutin mutations (35). Murakami et al. have described reduced but detectable IIH6-reactivity and intact alpha-DG in patients who are compound heterozygous for the fukutin retrotransposon insertion and a missense mutation (R179T or Q358P). These individuals showed minimal dystrophic features and normal intelligence. Laminin-binding activity is also retained in all cases. These findings provide further evidence that the disease severity of fukutin-deficient muscular dystrophy is related to the ratio of normal glycosylation to hypoglycosylation.
###end p 37
###begin p 38
###xml 281 283 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C38">38</xref>
###xml 319 326 311 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMGnT1</italic>
###xml 451 453 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C39">39</xref>
###xml 454 456 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C40">40</xref>
###xml 467 472 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 475 476 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C6">6</xref>
###xml 583 590 571 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">POMGnT1</italic>
###xml 926 928 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C18">18</xref>
###xml 1196 1198 1180 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C41">41</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 494 501 <span type="species:ncbi:9606">patient</span>
###xml 608 615 <span type="species:ncbi:9606">patient</span>
Such correlation has been observed in other dystroglycanopathies. LGMD2I patients at the severe end of the clinical spectrum tend to show the greatest reduction in alpha-DG glycosylation, while those at the milder end tend to have relatively well-preserved alpha-DG glycosylation (38). Most known missense mutations in POMGnT1 disrupt POMGnT enzyme activity, causing hypoglycosylation of alpha-DG and a severe congenital muscular dystrophy phenotype (39,40). Clement et al. (6) have reported a patient with a milder LGMD phenotype who carries a novel homozygous missense mutation in POMGnT1. Studies of this patient's fibroblasts showed an altered kinetic profile but intact enzyme activity, explaining the relatively mild phenotype. Furthermore, a recent systematic and large-scale study of genotype-phenotype correlation in dystroglycanopathy revealed a wide spectrum of clinical severity in specific disease-causing genes (18). A broad correlation between the amount of depleted glycosylated epitope and phenotypic severity was described, though not systematically quantified. A more recent study reported a few cases with less correlation between clinical course and alpha-DG immunolabeling (41). We propose that, in addition to immunolabeling, combination of western blotting and laminin binding assays will be necessary for further advances in both clinical and basic biomedical research.
###end p 38
###begin p 39
###xml 511 513 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C18">18</xref>
###xml 829 831 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C26">26</xref>
###xml 1063 1064 1039 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 1081 1083 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C42">42</xref>
###xml 1161 1169 1133 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1178 1185 1150 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1225 1228 1197 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 1235 1237 1207 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C26">26</xref>
###xml 1257 1262 1229 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 1273 1276 1245 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 1389 1396 1361 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1411 1416 1383 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 1510 1513 1478 1481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 1229 1233 <span type="species:ncbi:10090">mice</span>
###xml 1277 1281 <span type="species:ncbi:10090">mice</span>
###xml 1514 1518 <span type="species:ncbi:10090">mice</span>
The present study strongly suggests that full recovery of alpha-DG glycosylation is not always necessary; partial restoration of alpha-DG glycosylation might be enough to prevent or slow disease progression. The simplest way to restore alpha-DG glycosylation in dystroglycanopathies would be by replacing a defective gene with the normal version. In many cases, though, the disease-causing gene is not known. A recent study revealed that most patients with a dystroglycanopathy harbor mutations in novel genes (18). To increase amounts of glycosylated alpha-DG with laminin-binding activity regardless of the responsible gene, we took advantage of the observation that overexpression of LARGE can produce hyperglycosylated alpha-DG with increased laminin-binding activity in cells from genetically distinct dystroglycanopathies (26). LARGE-induced hyperglycosylation of alpha-DG has also been observed in both CHO glycosylation mutants showing defective transfer of sialic acid, galactose or fucose to glycoconjugates and in a mutant that is unable to synthesize O-mannose glycan (42). Such a 'super-effect' of LARGE on alpha-DG glycosylation has been observed in vitro, but no in vivo study has been reported except in Largemyd mice (26). Gene transfer of LARGE into Largemyd mice essentially replaces the defective gene with the normal version of the gene. Our results provide the first in vivo evidence that LARGE gene transfer can bypass the glycosylation defects of alpha-DG in models other than the Largemyd mice. These results support the idea that glycotherapies aimed at modulating LARGE may be a therapeutic option for many alpha-DG glycosylation-deficient muscular dystrophies.
###end p 39
###begin p 40
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Overall, our biochemical, histological and gene transfer experiments using novel model mice with disease-causing mutations support the efficacy of glycotherapy in dystroglycanopathies. The models developed here will be powerful in understanding the pathomechanism of FCMD and other related diseases.
###end p 40
###begin title 41
MATERIALS AND METHODS
###end title 41
###begin title 42
###xml 20 24 <span type="species:ncbi:10090">mice</span>
Generation of model mice
###end title 42
###begin p 43
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C43">43</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C44">44</xref>
###xml 244 251 244 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F1">1</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F1">1</xref>
###xml 472 479 468 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 531 532 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F1">1</xref>
###xml 726 727 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN387F1">1</xref>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 238 243 <span type="species:ncbi:10090">mouse</span>
###xml 356 361 <span type="species:ncbi:10090">mouse</span>
###xml 466 471 <span type="species:ncbi:9606">human</span>
###xml 785 790 <span type="species:ncbi:9606">human</span>
###xml 847 852 <span type="species:ncbi:9606">human</span>
###xml 884 889 <span type="species:ncbi:9606">human</span>
###xml 890 897 <span type="species:ncbi:9606">patient</span>
###xml 1007 1011 <span type="species:ncbi:10090">mice</span>
A targeting vector containing the retrotransposal insertion of human FCMD patients was generated using a site-directed DNA integration technique (43). Briefly, lox71 and TK-loxP-neo pA fragments (44) were inserted 5' and 3' to exon 10 of mouse fukutin (Fig. 1A, no. 2). To excise a floxed part of exon 10 (Fig. 1A, no. 3 Deltaexon10), Cre was expressed in mouse embryonic stem (ES) cells. Meanwhile, lox66 and TK-loxP fragments were inserted 5' and 3' to exon 10 of human fukutin, with or without a retrotransposal insertion (Fig. 1A, nos 4 and 5). Each construct was co-transfected with a Cre-expressing vector into ES cells that constitutively express the Deltaexon10 construct, to obtain recombinant knock-in alleles (Fig. 1A, nos 6 and 7). The transgenic alleles containing normal human exon 10 and mutant exon 10 were named Hn (representing 'human normal') and Hp (representing 'human patient'), respectively. Targeted ES cell clones were injected into blastocysts, and germline-competent heterozygous mice were in turn mated to generate homozygous mutants.
###end p 43
###begin p 44
###xml 372 379 348 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 420 427 396 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 460 462 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C45">45</xref>
###xml 481 488 457 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
Genotyping of each transgene was performed using PCR with the following primers: FCMDKIF1, GAAACTCTGCCATGACACCTC: HNC440R, ACCAGCTTAAATGCCCAGAAG: Wild R2, GAAGCCAACTGTGTACCACAC. The FCMDKIF1 and HNC440R, and FCMDKIF1 and Wild R2 primer pairs yielded bands of approximately800 bp (knock-in allele) and approximately1100 bp (wild-type allele), respectively. Genotyping of a fukutin allele disruption by a neo replacement (fukutin null) was described previously (45). The primers for fukutin RT-PCR are AGGGAATGGGCTGGTAGACT and GTGCCATTTTGGGACAAGTT.
###end p 44
###begin p 45
###xml 58 61 58 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myd</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 110 114 <span type="species:ncbi:10090">Mice</span>
C57BL/6 mice were obtained from Japan SLC, Inc., and Largemyd mice were obtained from The Jackson Laboratory. Mice were maintained in accordance with the animal care guidelines of Otsuka Pharmaceutical Co. Ltd. and Osaka University.
###end p 45
###begin title 46
Antibodies
###end title 46
###begin p 47
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
###xml 133 138 <span type="species:ncbi:10090">mouse</span>
###xml 242 246 <span type="species:ncbi:9925">goat</span>
###xml 368 373 <span type="species:ncbi:10090">mouse</span>
Antibodies used in western blots and immunofluorescence were as follows: mouse monoclonal antibody 8D5 against beta-DG (Novacastra); mouse monoclonal antibody IIH6 against alpha-DG (Upstate); and polyclonal anti-laminin (Sigma). We generated goat polyclonal antibodies against alpha-DG core protein using GST fusion proteins containing the N- or C-terminal domains of mouse alpha-DG. Antisera (074G) were affinity-purified using an alpha-DG-Fc fusion protein expressed in HEK293 cells. The purified antibody was named AP-074G-C.
###end p 47
###begin title 48
Dystroglycan preparation and western blotting
###end title 48
###begin p 49
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C20">20</xref>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C29">29</xref>
###xml 675 676 661 662 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 676 677 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 934 945 <span type="species:ncbi:3704">horseradish</span>
DG was enriched from solubilized skeletal muscle as previously described (20,29). Briefly, 100 mg of muscle was solubilized in 1 ml of Tris-buffered saline (TBS) containing 1% Triton X-100 and protease inhibitors (Funakoshi). The solubilized fraction was incubated with 30 microl of WGA-agarose beads (Vector Labs) at 4degreesC for 16 h. Beads were washed three times in 1 ml TBS containing 0.1% Triton X-100 and protease inhibitors. The beads were then either directly boiled for 5 min in SDS-polyacrylamide gel electrophoresis (PAGE) loading buffer (western blot and laminin overlay) or eluted with 300 microl TBS containing 0.1% Triton X-100, protease inhibitors and 300 mmN-acetylglucosamine (solid-phase binding assay). Proteins were separated using 7.5% or 10% SDS-PAGE. Gels were transferred to polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA, USA). Blots were probed with DG antibodies and then developed with horseradish peroxidase (HRP)-enhanced chemiluminescence (Supersignal West Pico, Pierce; or ECL Plus, GE Healthcare).
###end p 49
###begin title 50
Immunofluorescence and histological analysis
###end title 50
###begin p 51
###xml 1128 1130 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C34">34</xref>
###xml 326 330 <span type="species:ncbi:9925">goat</span>
###xml 344 349 <span type="species:ncbi:10090">Mouse</span>
###xml 615 620 <span type="species:ncbi:10090">mouse</span>
###xml 1052 1056 <span type="species:ncbi:10090">mice</span>
Cryosections (7 microm) were prepared and analyzed using immunofluorescence or H&E staining. Sections were stained for 2 min in hematoxylin, 1 min in eosin and then dehydrated with ethanol and xylenes. For immunofluorescence staining with IIH6, sections were treated with cold ethanol/acetone (1:1) for 1 min, blocked with 5% goat serum in MOM Mouse Ig Blocking Reagent (Vector Laboratories) at room temperature for 1 h and then incubated with primary antibodies diluted in MOM Diluent (Vector Laboratories) overnight at 4degreesC. The slides were washed with PBS and incubated with Alexa Fluor 488-conjugated anti-mouse IgM antibody (Molecular Probes) at room temperature for 30 min. For GFP detection, sections were fixed with 4% paraformaldehyde in PBS for 10 min, washed with PBS three times and then mounted. Permount(R) (Fisher Scientific) and TISSU MOUNT(R) (Shiraimatsu Kikai) were used for H&E staining and immunofluorescence, respectively. Sections were observed under fluorescence microscopy (Leica DMR, Leica Microsystems). For EBD uptake, mice were exercised on a treadmill (MK-680S, Muromachi Kikai) as described (34).
###end p 51
###begin title 52
Laminin-binding assay
###end title 52
###begin p 53
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C20">20</xref>
###xml 279 280 279 280 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 303 304 303 304 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 314 315 314 315 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 320 321 320 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 326 327 326 327 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 332 333 332 333 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 155 160 <span type="species:ncbi:10090">mouse</span>
###xml 559 565 <span type="species:ncbi:9986">rabbit</span>
Laminin-binding activity was examined as previously reported (20) with slight modifications. Laminin overlay assays were performed on PVDF membranes using mouse Engelbreth-Holm-Swarm (EHS) laminin (Sigma). Briefly, PVDF membranes were blocked in laminin-binding buffer (LBB: 10 mm triethanolamine, 140 mm NaCl, 1 mm MgCl2, 1 mm CaCl2, pH 7.6) containing 5% non-fat dry milk followed by incubation with 7.5 nM laminin at 4degreesC for 12 h in LBB with 3% BSA. Membranes were washed and incubated with anti-laminin (Sigma) at 4degreesC for 3 h followed by anti-rabbit IgG-HRP at room temperature for 45 min. Blots were developed by enhanced chemiluminescence (Supersignal West Pico, Pierce).
###end p 53
###begin p 54
###xml 417 418 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</italic>
###xml 457 458 451 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 459 460 453 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 500 501 494 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 503 504 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 583 584 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 585 586 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 586 589 580 583 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 589 590 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 592 593 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 593 594 587 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 595 596 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 605 606 599 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 606 607 600 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
###xml 638 639 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 658 659 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 659 662 653 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 212 217 <span type="species:ncbi:10090">Mouse</span>
###xml 378 384 <span type="species:ncbi:9986">rabbit</span>
For the solid-phase binding assay, WGA eluates were diluted 1:50 in TBS and coated on polystyrene ELISA microplates (Costar) for 16 h at 4degreesC. Plates were washed in LBB and blocked for 2 h in 3% BSA in LBB. Mouse EHS laminin was diluted in LBB and applied for 1 h. Wells were washed with 3% BSA in LBB, incubated for 1 h with 1:10,000 anti-laminin (Sigma) followed by anti-rabbit HRP. Plates were developed with o-phenylenediamine dihydrochloride and H2O2, then reactions were stopped with 2 N H2SO4 and values obtained on a microplate reader. The data were fit to the equation A=Bmaxx/(Kd+x), where Kd is the dissociation constant, A is absorbance and Bmax is maximal binding.
###end p 54
###begin title 55
Adenoviral gene transfer
###end title 55
###begin p 56
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C46">46</xref>
###xml 169 176 169 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 181 184 181 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GFP</italic>
###xml 418 425 418 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fukutin</italic>
###xml 468 473 468 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C46">46</xref>
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
The complete open reading frame of mouse fukutin was cloned into the EcoRI site of the pKSCX-EGFP vector (46). The pKSCX-EGFP vector contains IRES-EGFP so that both the fukutin and GFP genes are expressed bicistronically under the CAG promoter. This expression cassette was digested with SwaI, and then its blunt-ended fragment was ligated into the adenoviral cosmid vector. The recombinant adenoviral vector encoding fukutin was generated using the method of Tashiro et al. (46).
###end p 56
###begin p 57
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LARGE</italic>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN387C26">26</xref>
Generation of the recombinant adenoviral vector encoding LARGE has been previously described (26). Amplified adenoviruses were purified using VIVAPURE ADENOPACK 100 (VIVASCIENCE).
###end p 57
###begin p 58
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 180 181 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 142 146 <span type="species:ncbi:9913">calf</span>
In vivo gene transfer was performed with Hp/- and control littermate Hp/+ pups, age 2-4 d. Adenoviruses were injected percutaneously into the calf and hamstring with 1 x 108-1 x 109 particles in 10 microl of saline solution. Mock injections used saline solution only. Four weeks after injection, experimental and control contralateral leg muscles were subjected to immunofluorescence and biochemical analysis.
###end p 58
###begin title 59
SUPPLEMENTARY MATERIAL
###end title 59
###begin p 60
.
###end p 60
###begin title 61
FUNDING
###end title 61
###begin p 62
###xml 31 77 31 77 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ministry of Health, Labor and Welfare of Japan</grant-sponsor>
###xml 212 218 212 218 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">17A-10</grant-num>
###xml 229 271 229 271 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Japan Society for the Promotion of Science</grant-sponsor>
###xml 313 321 313 321 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">19790232</grant-num>
###xml 332 368 332 368 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mizutani Foundation for Glycoscience</grant-sponsor>
###xml 388 460 388 460 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ministry of Education, Culture, Sports, Science, and Technology of Japan</grant-sponsor>
This work was supported by the Ministry of Health, Labor and Welfare of Japan (Research on Psychiatric and Neurological Diseases and Mental Health H20-016, and The Research Grant for Nervous and Mental Disorders 17A-10 to T.T.); Japan Society for the Promotion of Science (a Grant-in-Aid for Young Scientists (B) 19790232 to M.K.); Mizutani Foundation for Glycoscience (to K.K.); and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (the 21st Century COE program 14013037). Funding to pay the Open Access charge was provided by Research on Psychiatric and Neurological Diseases and Mental Health H20-016.
###end p 62
###begin title 63
Supplementary Material
###end title 63
###begin title 64
[Supplementary Data]
###end title 64
###begin title 65
ACKNOWLEDGEMENTS
###end title 65
###begin p 66
We would like to thank past and present members of the Clinical Genetics laboratory for fruitful discussions and scientific contributions. We also thank Norihiro Miyazawa and Takashi Wadatsu for technical supports and Dr Jennifer Logan for help in editing the manuscript.
###end p 66
###begin p 67
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement</italic>
Conflict of Interest statement. None declared.
###end p 67
###begin title 68
REFERENCES
###end title 68
###begin article-title 69
Glycobiology of neuromuscular disorders
###end article-title 69
###begin article-title 70
Defective glycosylation in congenital muscular dystrophies
###end article-title 70
###begin article-title 71
Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C
###end article-title 71
###begin article-title 72
A novel form of recessive limb girdle muscular dystrophy with mental retardation and abnormal expression of alpha-dystroglycan
###end article-title 72
###begin article-title 73
Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy
###end article-title 73
###begin article-title 74
Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant
###end article-title 74
###begin article-title 75
Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1
###end article-title 75
###begin article-title 76
Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity
###end article-title 76
###begin article-title 77
###xml 51 56 <span type="species:ncbi:9606">human</span>
Dystroglycan: from biosynthesis to pathogenesis of human disease
###end article-title 77
###begin article-title 78
###xml 54 60 <span type="species:ncbi:9913">bovine</span>
Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin
###end article-title 78
###begin article-title 79
Congenital progressive muscular dystrophy of the Fukuyama type - clinical, genetic and pathological considerations
###end article-title 79
###begin article-title 80
Aberrant neuromuscular junctions and delayed terminal muscle fiber maturation in alpha-dystroglycanopathies
###end article-title 80
###begin article-title 81
An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy
###end article-title 81
###begin article-title 82
Novel mutations and genotype-phenotype relationships in 107 families with Fukuyama-type congenital muscular dystrophy (FCMD)
###end article-title 82
###begin article-title 83
Structural organization, complete genomic sequences and mutational analyses of the Fukuyama-type congenital muscular dystrophy gene, fukutin
###end article-title 83
###begin article-title 84
###xml 53 60 <span type="species:ncbi:9606">patient</span>
A new mutation of the fukutin gene in a non-Japanese patient
###end article-title 84
###begin article-title 85
A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype
###end article-title 85
###begin article-title 86
Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan
###end article-title 86
###begin article-title 87
###xml 8 16 <span type="species:ncbi:9606">patients</span>
Two new patients bearing mutations in the fukutin gene confirm the relevance of this gene in Walker-Warburg syndrome
###end article-title 87
###begin article-title 88
Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies
###end article-title 88
###begin article-title 89
###xml 128 133 <span type="species:ncbi:10090">mouse</span>
Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation-deficient muscle-eye-brain disorders
###end article-title 89
###begin article-title 90
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse
###end article-title 90
###begin article-title 91
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family
###end article-title 91
###begin article-title 92
###xml 17 22 <span type="species:ncbi:9606">human</span>
Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan
###end article-title 92
###begin article-title 93
Molecular recognition by LARGE is essential for expression of functional dystroglycan
###end article-title 93
###begin article-title 94
LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies
###end article-title 94
###begin article-title 95
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Basement membrane fragility underlies embryonic lethality in fukutin-null mice
###end article-title 95
###begin article-title 96
Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development
###end article-title 96
###begin article-title 97
Disruption of perlecan binding and matrix assembly by post-translational or genetic disruption of dystroglycan function
###end article-title 97
###begin article-title 98
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle
###end article-title 98
###begin article-title 99
Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy
###end article-title 99
###begin article-title 100
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Ocular abnormalities in Large(myd) and Large(vls) mice, spontaneous models for muscle, eye, and brain diseases
###end article-title 100
###begin article-title 101
###xml 48 52 <span type="species:ncbi:10090">mice</span>
A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1)
###end article-title 101
###begin article-title 102
###xml 104 108 <span type="species:ncbi:10090">mice</span>
A common disease-associated missense mutation in alpha-sarcoglycan fails to cause muscular dystrophy in mice
###end article-title 102
###begin article-title 103
Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness
###end article-title 103
###begin article-title 104
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy
###end article-title 104
###begin article-title 105
Genetic compensation for sarcoglycan loss by integrin alpha7beta1 in muscle
###end article-title 105
###begin article-title 106
Abnormalities in alpha-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies
###end article-title 106
###begin article-title 107
Loss-of-function of an N-acetylglucosaminyltransferase, POMGnT1, in muscle-eye-brain disease
###end article-title 107
###begin article-title 108
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Protein O-mannosyltransferase activities in lymphoblasts from patients with alpha-dystroglycanopathies
###end article-title 108
###begin article-title 109
Comparative study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity
###end article-title 109
###begin article-title 110
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse large can modify complex N- and mucin O-glycans on alpha-dystroglycan to induce laminin binding
###end article-title 110
###begin article-title 111
Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan
###end article-title 111
###begin article-title 112
Targeted integration of DNA using mutant lox sites in embryonic stem cells
###end article-title 112
###begin article-title 113
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
Effects of fukutin deficiency in the developing mouse brain
###end article-title 113
###begin article-title 114
Constructing adenoviral vectors by using the circular form of the adenoviral genome cloned in a cosmid and the Cre-loxP recombination system
###end article-title 114

